Who
Rita A. Karachun
Director
Company insider
Files Form 4 as: Director, Coherus Oncology; Sr. VP Fince-Global Controller, Merck & Company.
In numbers
- Trades disclosed
- 108
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $12.9M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 4 May 2014
- Last trade
- 5 Jun 2026
- Last filed
- 9 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 9 Jun 2026 | CHRS Coherus OncologyBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CHRS Coherus OncologyBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 12 Jun 2025filed 13 Jun 2025 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —112,000 at $0.00 | filing |
| 4 Jun 2024filed 5 Jun 2024 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —168,000 at $0.00 | filing |
| 4 May 2023filed 5 May 2023 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —949 at $0.00 | filing |
| 4 May 2023filed 5 May 2023 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —15,875 at $0.00 | filing |
| 4 May 2023filed 5 May 2023 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $112K949 at $118.22 | filing |
| 4 May 2023filed 5 May 2023 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code F | $39K326 at $118.22 | filing |
| 4 May 2023filed 5 May 2023 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $985K15,875 at $62.07 | filing |
| 4 May 2023filed 5 May 2023 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $1.9M15,875 at $117.53 | filing |
| 3 May 2023filed 5 May 2023 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —803 at $0.00 | filing |
| 3 May 2023filed 5 May 2023 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $95K803 at $117.89 | filing |
| 3 May 2023filed 5 May 2023 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code F | $33K276 at $117.89 | filing |
| 2 May 2023filed 4 May 2023 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —9,682 at $0.00 | filing |
| 2 May 2023filed 4 May 2023 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,781 at $0.00 | filing |
| 1 May 2023filed 3 May 2023 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —930 at $0.00 | filing |
| 1 May 2023filed 3 May 2023 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $107K930 at $115.47 | filing |
| 1 May 2023filed 3 May 2023 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code F | $37K319 at $115.47 | filing |
News
Merck & Co., Inc. $MRK Stock Sold by Smith Chas P & Associates PA CpasMRK · dailypolitical.com · 22 Oct 2026Merck's KEYTRUDA Plus Padcev Wins EU Approval For Muscle-Invasive Bladder CancerMRK · rttnews.com · 21 Oct 2026Contrasting Merck & Co., Inc. (NYSE:MRK) and ABVC BioPharma (NASDAQ:ABVC)MRK · themarketsdaily.com · 21 Oct 2026
0 headlines in the last 90 days name Rita A. Karachun; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.